These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34565676)

  • 21. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer.
    Tsuyoshi H; Inoue D; Kurokawa T; Yoshida Y
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1661-1671. PubMed ID: 32715605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
    Schwameis R; Chiva L; Harter P
    Int J Gynecol Cancer; 2022 Apr; 32(4):578. PubMed ID: 35121632
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels.
    Zhang M; Bao Y; Zhang H; Li D; Mei X; Cheng X
    J Obstet Gynaecol; 2023 Dec; 43(1):2204940. PubMed ID: 37186893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review.
    Hotouras A; Desai D; Bhan C; Murphy J; Lampe B; Sugarbaker PH
    Int J Gynecol Cancer; 2016 May; 26(4):661-70. PubMed ID: 26844612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
    Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
    Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
    Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL
    Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
    Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
    Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
    Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
    Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
    Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI).
    Steffen T; Häller L; Bijelic L; Glatzer M; Glehen O; Goéré D; de Hingh I; Li Y; Moran BJ; Morris DL; Piso P; Quadros CA; Rau B; Sugarbaker P; Yonemura Y; Putora PM
    Oncology; 2021; 99(1):41-48. PubMed ID: 32920557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on "Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer-A Phase 3 Clinical Trial".
    Noiret B; Bakrin N; Eveno C
    Ann Surg Oncol; 2022 May; 29(5):3357-3358. PubMed ID: 35192155
    [No Abstract]   [Full Text] [Related]  

  • 33. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer.
    Bhatt A; Glehen O; Zivanovic O; Brennan D; Nadeau C; Van Driel W; Bakrin N
    Ann Surg Oncol; 2023 Dec; 30(13):8115-8137. PubMed ID: 37561343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer].
    Schmalfeldt B
    Chirurgie (Heidelb); 2022 Dec; 93(12):1144-1151. PubMed ID: 36201013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is peritonectomy and hyperthermic intraperitoneal chemotherapy a new standard of treatment for advanced epithelial ovarian cancer?
    Farrell R
    Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):335-340. PubMed ID: 30706448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer.
    Mutlu Sütcüoğlu B; Sütcüoğlu O
    Lancet Oncol; 2023 Dec; 24(12):e457. PubMed ID: 38039999
    [No Abstract]   [Full Text] [Related]  

  • 37. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
    Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer.
    Wang JY; Gross M; Urban RR; Jorge S
    Curr Treat Options Oncol; 2024 Mar; 25(3):313-329. PubMed ID: 38270801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study.
    Manzanedo I; Pereira F; Serrano Á; Pérez-Viejo E; Martínez-Torres B; Carrión L; Calzas J
    Clin Transl Oncol; 2019 Oct; 21(10):1357-1363. PubMed ID: 30788835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
    Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
    Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.